Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab-Reference-Cited by-同舟云学术

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Published:2015-03 Issue:3 Volume:13 Page:522-530.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Yanai Henit,Lichtenstein Lev,Assa Amit,Mazor Yoav,Weiss Batia,Levine Arie,Ron Yulia,Kopylov Uri,Bujanover Yoram,Rosenbach Yoram,Ungar Bella,Eliakim Rami,Chowers Yehuda,Shamir Raanan,Fraser Gerald,Dotan Iris,Ben-Horin Shomron

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Review article: loss of response to anti-TNF treatments in Crohn's disease;Ben-Horin;Aliment Pharmacol Ther,2011

2. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review;Billioud;Am J Gastroenterol,2011

3. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009

4. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease;Ainsworth;Am J Gastroenterol,2008

5. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease;Baert;N Engl J Med,2003

Cited by 272 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study;BioDrugs;2024-08-22

2. How comparative studies can inform treatment decisions for Crohn’s disease;Expert Opinion on Biological Therapy;2024-08-12

3. Infliximab Tissue Concentrations in Patients With Stable Ulcerative Colitis Are Correlated With More Durable Infliximab-associated Disease Remission;Inflammatory Bowel Diseases;2024-05-08

4. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

5. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05